12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

EMA's CHMP issued a positive opinion to extend the indication for Xarelto rivaroxaban from Bayer to include treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE...

Read the full 150 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >